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INTRODUCTION
============

It is estimated that familial susceptibility to breast cancer accounts for about 25% of all breast cancer cases \[[@r1]\]. The testing for germline mutations in high-penetrance breast cancer predisposition genes has become standard practice for breast cancer patients \[[@r2]\]. In clinical practice, *BRCA1/2* are the most widely tested genes, particularly for breast cancer patients diagnosed at young age, with triple negative breast cancer (TNBC), or have a significant family history of breast, ovarian, or other related cancers \[[@r3]\]. Currently, existing recommendations for germline mutation testing of other high-penetrance genes including *CDH1, TP53* and *PTEN* are based on specific clinical features \[[@r4]\]. Meanwhile, numerous studies have associated mutations in moderate-penetrance genes, including *PALB2*, *ATM*, *CHEK2*, *BRIP1,* with increased breast cancer risk of two to four-fold compared to the 10% risk of the general population \[[@r5]\]. Germline *PALB2* mutations have been reported to play significant roles in hereditary breast cancer, with a five-fold or greater breast cancer risk for mutation carriers \[[@r6]--[@r8]\]. In addition, germline mutations in DNA damage repair genes such as *ATM* and *CHEK2* are also associated with an increased risk of breast cancer \[[@r9], [@r10]\]. Despite mounting evidence suggesting the association of mutations in moderate-penetrance genes with increased breast cancer risk, the current guidelines still do not require the testing of these genes. Thus far, no consensus exists on the number and the specific genes needed to be sequenced and analyzed for the assessment of genetic cancer predisposition \[[@r11]\].

Although harboring germline mutations in either high- or moderate-penetrance genes will increase the predisposition to develop breast cancer, mutations in any one of these genes are rare and testing one gene at a time is both expensive and inefficient \[[@r12]\]. Recent advances in next-generation sequencing (NGS) have made multigene panels more affordable and allowed it to be increasingly used in cancer risk assessment in clinical practice \[[@r13], [@r14]\]. However, as compared to America and Europe, the use of multigene panel in cancer risk assessment of breast cancer patients is still relatively unpopular in Asia \[[@r15]\]. Expanded multigene panel testing can reveal incidental findings of germline variants in addition to the detection of somatic mutations in highly actionable genes \[[@r16]\]. The detection of likely pathogenic or pathogenic (LP/P) germline variants in low and moderate-risk genes as well as variants of uncertain significance (VUS) also challenges the established genetic counseling repertoire \[[@r17], [@r18]\]. Moreover, sequencing with multigene panels can identify significant gaps to further understand the relationship between genetics and tumor biology \[[@r19]\].

Numerous studies on germline mutation testing were focused on patients with family history of cancer \[[@r20], [@r21]\]. Current guidelines require only the patients with known family history to undergo genetic testing; however, not all patients with germline mutations have a known family history of tumors, which results in missing about 50% to 80% of individuals at risk \[[@r22], [@r23]\]. With growing evidence associating germline mutations with cancer predisposition as well as the availability of targeted therapies, the current view is that all patients newly diagnosed with cancer should be tested for germline mutations, which has the potential to reduce disease burden through secondary prevention and explore targeted therapies \[[@r24]\].

In order to promote the use of multigene panel testing of breast cancer patients, we need to understand the prevalence of germline mutations particularly in cancer predisposition genes beyond *BRCA1/2* to identify the genes commonly mutated in our population. Moreover, the somatic mutation profiles of patients who harbor germline BRCA and non-BRCA mutations remain unexplored. In this study, we interrogated the germline and somatic mutational profile of 524 Chinese breast cancer patients with various stages unselected for predisposing factors, such as age at onset or family history, using a panel consisting of 520 cancer-related genes, including 62 cancer susceptibility genes ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Our study aims to examine the prevalence of germline mutations in known breast cancer predisposition genes and other cancer-associated genes and to evaluate the clinical value of multigene panel testing of germline mutations in this population. We also assessed the relationship between clinicopathologic characteristics and germline mutation status and identified the somatic mutations among germline mutation carriers.

RESULTS
=======

Study population
----------------

A total of 524 breast cancer patients consented to NGS testing and were offered disclosure of germline results under a separate protocol. Clinical and pathologic features for study patients are provided in [Table 1](#t1){ref-type="table"}. The mean age at diagnosis was 49.2 years (range, 22 to 86 years). Except for 1 male, all the other 523 patients were females. Most of the patients were diagnosed at stage I (124 cases), II (231 cases) and III (102 cases), while the remaining 67 patients had stage IV. Majority of the patients (82.4%, 432/524) were diagnosed with invasive ductal cancer. Overall, 55 (32.0%) patients reported having a family history of breast or ovarian cancer and 55 (32.0%) patients reported having family history of other cancer. The remaining patients reported no family history of cancer.

###### Clinicopathologic features of the study patients.

  ------------------------------------------------ --------- --------
  **Characteristics**                              **No.**   **%**
  **Age**                                                    
   ≤40 years                                       96        18.32%
   \> 40 years                                     428       81.68%
  **Menopausal status**                                      
   Pre                                             280       53.44%
   Post                                            231       44.08%
   Unknown                                         12        2.29%
   Male                                            1         0.19%
  **Family history of breast or ovarian cancer**             
   Yes                                             93        17.75%
   No                                              330       62.98%
   Unknown                                         101       19.27%
  **Tumor size**                                             
   ≤2 cm                                           199       37.98%
   \> 2 cm                                         303       57.82%
   Unknown                                         22        4.20%
  **Lymph nodes status**                                     
   Negative                                        256       48.85%
   Positive                                        247       47.14%
   Unknown                                         21        4.01%
  **Grade**                                                  
   I                                               23        4.39%
   II                                              234       44.66%
   III                                             234       44.66%
   Unknown                                         33        6.30%
  **Histology**                                              
   DCIS                                            14        2.67%
   Infiltrating Ductal Carcinoma                   457       87.21%
   Infiltrating Lobular                            10        1.91%
  Carcinoma                                                  
   Other, specify                                  23        4.39%
   Unknown                                         20        3.82%
  **ER status**                                              
   Negative                                        139       26.53%
   Positive                                        363       69.27%
   Unknown                                         22        4.20%
  ------------------------------------------------ --------- --------

Frequency and characteristics of deleterious germline mutations
---------------------------------------------------------------

Paired white blood cell and tumor samples from 524 breast cancer patients were sequenced using a panel consisting of 520 cancer-related genes including 62 cancer susceptibility genes to interrogate the germline and somatic mutations, respectively.

Analysis revealed the detection of 76 likely pathogenic or pathogenic (LP/P) mutations in 15 cancer susceptibility genes from 58 patients (11.1%, 58/524) ([Figure 1](#f1){ref-type="fig"}). Interestingly, 2 (0.38%) patients had more than one concurrent LP/P germline variants, with *TP53* (c.919+1G\>T) and *PMS2* (p.R287fs) mutations detected in a patient with luminal B tumor, and *BRCA2* (p.Q1129\*) and *FANCI* (c.158-2A\>G) mutations detected in a patient with luminal A tumor.

![**Frequency and distribution of LP/P germline variants.** LP/P mutations identified in 62 cancer susceptibility genes in 524 unselected breast cancer patients. The multiples of genes associated with breast cancer risk are listed on the histogram.](aging-12-102783-g001){#f1}

Twenty-nine (5.53%, 29/524) patients carried germline *BRCA1/2* mutation; including 11 (2.10%, 11/524) patients with *BRCA1* and 18 (3.44%, 18/524) patients with *BRCA2* mutations. As shown in [Figure 2A](#f2){ref-type="fig"}--[2B](#f2){ref-type="fig"}, BRCA1 T1691K (n = 2) and I1824fs (n = 2) and BRCA2 A938fs (n = 3) were the most frequent LP/P germline *BRCA1/2* mutations in our cohort. In addition, 30 (5.72%) patients carried a total of 38 LP/P mutations in other cancer susceptibility genes beyond *BRCA1/2*. Mutations in genes beyond *BRCA1/2* detected in the cohort included *MUTYH* (n = 4), *PALB2* (n = 4), *ATM* (n = 3), *BRIP1* (n = 3), *CDH1* (n = 3), *RAD51C* (n = 3), *CHEK2* (n = 2), *FANCA* (n = 2), *PMS2* (n = 2), *TP53* (n = 2), *FANCI* (n = 1), *FANCL* (n = 1) and *PTEN* (n = 1). Interestingly, among the 15 genes with germline mutations, 7 genes belong to Fanconi anaemia family of genes, including *BRCA2*, *PALB2*, *BRIP1*, *RAD51C*, *FANCA*, *FANCI* and *FANCL*, with 53.4% (31/58) of the patients carrying germline mutations in any of these genes. No LP/P germline mutations were found in the remaining 47 cancer susceptibility genes included in the panel. All the LP/P germline mutations detected in our cohort were listed in [Table 2](#t2){ref-type="table"}.

![**LP/P germline *BRCA1/2* mutations detected in this cohort.** (**A**) 11 LP/P mutations found in *BRCA1*. (**B**) 18 LP/P mutations found in *BRCA2.* Colored boxes depict the different functional domains along the gene. Small colored circles denote the type of mutation while the location of the circle specifies the mutation site. A patient is represented by a circle. The length of the lollipop represents the number of people of a specific variant.](aging-12-102783-g002){#f2}

###### The list of likely pathogenic and pathogenic mutations detected in the cohort.

  --------------- ---------- ------------------------- ----------------- -------- ------------------- ----------------------------------------
  **Sample ID**   **Gene**   **Mutation type**         **Description**   **AF**   **Degrees**         **Public database or published paper**
  RS1829111TIS    ATM        frameshift variant        p.L2081fs         78.90%   Likely pathogenic   N
  RSI 829631HS    ATM        stop gained               p.Y155\*          43.90%   Likely pathogenic   N
  RS1806623TIS    ATM        stop gained               p.E277\*          46.82%   Pathogenic          Y (clinvar)
  RS1810742TIS    BRCA1      splice region variant     p.T1691K          57.66%   Likely pathogenic   Y (clinvar)
  RSI 827051FFP   BRCA1      splice region variant     p.T1691K          72.22%   Likely pathogenic   Y (clinvar)
  RS1828137FFP    BRCA1      frameshift variant        p.H318fs          60.59%   Likely pathogenic   Y (PMID: 28724667)
  RS1834453TIS    BRCA1      frameshift variant        p.I1824fs         32.62%   Pathogenic          Y (PMID: 28724667)
  RS1803594FFP    BRCA1      splice region variant     c.5074+3A\>G      58.09%   Pathogenic          Y (clinvar)
  RS1726576TIS    BRCAl      missense variant          P-F1734L          80.27%   Likely pathogenic   Y (clinvar)
  RS1725206FFP    BRCA1      frameshift variant        p.I1824fs         40.06%   Pathogenic          Y (PMID: 28724667)
  RS1827494TIS    BRCAl      frameshift variant        p.P930fs          61.94%   Likely pathogenic   Y (PMID: 28724667)
  RS1829599FFP    BRCAl      frameshift variant        p.Q1323fs         64.93%   Pathogenic          N
  RSI 811823TIS   BRCAl      frameshift variant        p.L1306fs         84.90%   Pathogenic          Y (PMID: 28724667)
  RSI 804518FFP   BRCAl      splice donor variant      c.134+1G\>T       48.46%   Pathogenic          Y (clinvar)
  RS1815241TIS    BRCA2      frameshift variant        p.A938fs          52.73%   Pathogenic          Y (clinvar)
  RS1844984FFP    BRCA2      splice acceptor variant   c.-39-l\_-39del   36.90%   Pathogenic          Y (clinvar)
  RS1829456TIS    BRCA2      stop gained               p.Q1295\*         55.38%   Pathogenic          Y (clinvar)
  RS1803222TIS    BRCA2      frameshift variant        p.A2764fs         71.71%   Pathogenic          N
  RS1821585FFP    BRCA2      frameshift variant        p.V726fs          51.09%   Likely pathogenic   N
  RS1722724TIS    BRCA2      stop gained               p.W2626\*         67.38%   Pathogenic          Y (clinvar)
  RS1840694PLA    BRCA2      stop gained               p.Q1037\*         49.37%   Pathogenic          Y (clinvar)
  RSI 823761TIS   BRCA2      stop gained               p.S1882\*         82.53%   Pathogenic          Y (clinvar)
  RS1833574PLA    BRCA2      stop gained               P-Q1037\*         48.98%   Pathogenic          Y (clinvar)
  RS1841181FFP    BRCA2      splice donor variant      c.316+lG\>A       59.00%   Pathogenic          Y (clinvar)
  RS1723884TIS    BRCA2      stop gained               p.K944\*          57.95%   Pathogenic          Y (clinvar)
  RS1838903TIS    BRCA2      frameshift variant        p.T3033fs         57.11%   Pathogenic          Y (clinvar)
  RS1826534FFP    BRCA2      frameshift variant        p.N957fs          57.89%   Pathogenic          N
  RS1812099FFP    BRCA2      stop gained               p.Ql 129\*        87.60%   Pathogenic          Y (clinvar)
  RSI 800551FFP   BRCA2      frameshift variant        p.A938fs          54.00%   Pathogenic          Y (clinvar)
  RS1813609FFP    BRCA2      frameshift variant        p.W1692fs         62.10%   Likely pathogenic   Y (PMID: 26689913, PMID: 25415331)
  RS1801361TIS    BRCA2      frameshift variant        p.A938fs          56.82%   Pathogenic          Y (clinvar)
  RS1813932FFP    BRCA2      stop gained               p.E7\*            64.48%   Pathogenic          N
  RS1840466TIS    BRIP1      splice donor variant      c.627+lG\>A       64.39%   Pathogenic          Y (clinvar)
  RS1809229FFP    BRIP1      start lost                p.Ml?             40.17%   Pathogenic          Y (clinvar)
  RS1840704PLA    BRIP1      stop gained               P-R798\*          48.41%   Pathogenic          Y (clinvar)
  RS1828521TIS    CDH1       missense variant          p.T340A           45.90%   Likely pathogenic   Y (clinvar)
  RS1829332TIS    CDHl       missense variant          P-T340A           35.80%   Likely pathogenic   Y (clinvar)
  RS1830223FFP    CDH1       missense variant          p.T340A           43.68%   Likely pathogenic   Y (clinvar)
  RS1726142FFP    CHEK2      stop gained               p.R95\*           73.50%   Pathogenic          Y (clinvar)
  RSI 829637TIS   CHEK2      missense variant          p.H371Y           78.51%   Likely pathogenic   Y (clinvar)
  --------------- ---------- ------------------------- ----------------- -------- ------------------- ----------------------------------------

In addition to the LP/P variants, a total of 1,968 variants of uncertain clinical significance (VUS) in 62 cancer susceptibility genes were also detected in the cohort. At least one VUS was identified in 490 (93.5%) patients, with as many as three variants found per patient. Among them, 53 (10.8%) patients with a VUS also had an LP/P mutation. All the VUSs identified in our cohort are listed in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}.

Germline mutations according to breast cancer molecular subtype
---------------------------------------------------------------

We also analyzed the distribution of LP/P germline mutations according to the molecular subtypes of the patients. The distribution and mutation detection rates of the germline mutations detected in our cohort according to their molecular breast cancer subtypes were summarized in [Supplementary Tables 3](#SD1){ref-type="supplementary-material"} and [4](#SD1){ref-type="supplementary-material"}, respectively.

According to the distribution, germline mutations in the 15 cancer susceptibility genes were found among patients with HR+/HER2- breast tumors ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). The overall LP/P germline mutation detection rates were 14.8% (9/61) for patients with triple-negative tumors, 8.5% (5/59) for patients with HER2-enriched tumors, 12.4% (33/267) for patients with HR+/HER2- tumors, 8.5% (7/82) for patients with HR+/HER2+ tumors and 7.3% (4/55) for patients with unknown molecular subtype ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). No statistical difference was found for the germline mutation rate according to the molecular subtypes (P=0.4).

Clinicopathological features of germline mutations carriers
-----------------------------------------------------------

Next, we further analyzed the clinicopathological characteristics of the LP/P germline mutation carriers to understand predisposing factors associated with the germline mutations. Breast cancer was diagnosed at a significantly younger age in germline mutation carriers as compared to non-carriers (median age: 45 vs 50 years, P=0.011, [Table 3](#t3){ref-type="table"}). Consistent with a younger age of onset, premenopausal women were more likely to carry LP/P germline mutations (P=0.013). Moreover, germline mutation carriers were more likely to have a family history of breast and/or ovarian cancer (P=0.001, [Table 3](#t3){ref-type="table"}). However, no further significant correlations were found between germline mutation status and other clinicopathologic factors, including tumor size (P=0.561), lymph node status (P=0.731), grade (P=0.420), histology (P=0.973), ER status (P=0.733), PR status (P=0.673), HER2 status (P=0.514) and a triple-negative phenotype (P=0.416). In addition, we found no significant correlation in the clinicopathological characteristics of patients carrying germline mutations in BRCA versus non-BRCA (data not shown).

###### Clinicopathological characteristics between germline mutation carriers and non-carriers.

  ------------------------------------------------ ------------------ -------------------------------- ------------- -------- ----------
  **Characteristics**                              **Non-carriers**   **Germline mutation carriers**   **P-value**            
  **Age**                                                                                              0.011\*                
   Median (range)                                  50 (25-86)                                          45 (22-72)             
   \<40 years                                      78                 16.74%                           18            31.03%   
   \> 40 years                                     388                83.26%                           40            68.97%   
  **Menopausal status**                                                                                                       0.013a\*
   Pre                                             238                51.07%                           42            72.41%   
   Post                                            216                46.35%                           15            25.86%   
   Unknown                                         11                 2.36%                            1             1.72%    
   Male                                            1                  0.21%                            0             0.00%    
  **Family history of breast or ovarian cancer**                      \<0.001\*                                               
   Yes                                             65                 13.95%                           28            48.28%   
   No                                              311                66.74%                           19            32.76%   
   Unknown                                         90                 19.31%                           11            18.97%   
  **Tumor size**                                                                                                              0.561a
   ≤2 cm                                           179                38.41%                           20            34.48%   
   \> 2 cm                                         266                57.08%                           37            63.79%   
   Unknown                                         21                 4.51%                            1             1.72%    
  **Lymph nodes status**                                                                                                      0.731a
   Negative                                        226                48.50%                           30            51.72%   
   Positive                                        220                47.21%                           27            46.55%   
   Unknown                                         20                 4.29%                            1             1.72%    
  **Grade**                                                                                                                   0.420a
   I                                               21                 4.51%                            2             3.45%    
   II                                              212                45.49%                           22            37.93%   
   III                                             202                43.35%                           32            55.17%   
   Unknown                                         31                 6.65%                            2             3.45%    
  **Histology**                                    0.973a                                                                     
   DCIS                                            13                 2.79%                            1             1.72%    
   Infiltrating Ductal Carcinoma                   404                86.70%                           53            91.38%   
   Infiltrating Lobular Carcinoma                  9                  1.93%                            1             1.72%    
   Other, specify                                  21                 4.51%                            2             3.45%    
   Unknown                                         19                 4.08%                            1             1.72%    
  **ER status**                                    0.733a                                                                     
   Negative                                        124                26.61%                           15            25.86%   
   Positive                                        321                68.88%                           42            72.41%   
   Unknown                                         21                 4.51%                            1             1.72%    
  ------------------------------------------------ ------------------ -------------------------------- ------------- -------- ----------

Characteristics of somatic mutations in breast cancer patients with germline mutations
--------------------------------------------------------------------------------------

To understand the interplay between germline and somatic mutations in breast cancer patients, sequencing data derived from the paired tumor samples of the 524 breast cancer patients were analyzed. Genomic alterations with detection rate of more than 4% were shown in [Figure 3](#f3){ref-type="fig"}. Interestingly, somatic *TP53* mutations were detected in all (100%, 11/11) and a majority (67%, 2/3) of the patients with germline *BRCA1* and *CDH1* mutations, respectively. On the other hand, no somatic *TP53* mutations were detected in all the patients with germline *ATM* (n=3) and *TP53* (n=2). In addition, somatic mutations in *PIK3CA* were more frequent among patients with germline *CDH1* (3/3). Furthermore, a patient with pathogenic germline *PALB2* mutation (p.Q921fs) also had somatic *PALB2* mutation (p.D525fs).

![**Comprehensive somatic mutation spectrum of the 524 patients.** Each column represents a patient and each row represents a gene. The number on the left represents the percentage of patients with mutations in a specific gene. The top plot represents the overall number of mutations detected in a patient. Different colors denote different types of mutation. The annotation at the bottom, with each color representing each group, depicts the germline mutations carried by the patients.](aging-12-102783-g003){#f3}

Next, we divided the patients into three groups according to germline mutations: Germline-BRCA1/2, Germline-others (non-BRCA) and Others (non-carriers) ([Figure 4A](#f4){ref-type="fig"}). There was no difference in the somatic mutation detection rate among the three groups ([Figure 4B](#f4){ref-type="fig"}). Then, we analyzed the distribution of mutation types among the three groups ([Figure 4C](#f4){ref-type="fig"}). Germline-BRCA1/2 group had significantly more missense mutations (P=0.02) and less copy number amplification (P=0.04) than the Germline-others group. Meanwhile, mutation types between Germline-others group and Others group were not statistically different (P\>0.05). Moreover, the mutation rates of *AKT1*, *CCND1*, *FGFR1*, and *PIK3CA* were different among the three groups ([Figure 4D](#f4){ref-type="fig"} and [Supplementary Table 5](#SD3){ref-type="supplementary-material"}). Mutations in *AKT1* and *CCND1* were not detected in the Germline-BRCA1/2 group. *FGFR1* mutation rate was 24% in Germline-others group, 10% in Germline- BRCA1/2 group, and 9% in Others group. The *PIK3CA* mutation rate was significantly lower in Germline- BRCA1/2 group than the other two groups (Germline-BRCA1/2 vs Germline-others P=0.02; Germline-BRCA1/2 vs Others P=0.002). As shown in [Figure 4E](#f4){ref-type="fig"}, PIK3CA H1047R was the hotspot mutation detected from all three groups. The Others group had significantly more missense *PIK3CA* mutations than the Germline-others group (P=0.02).

![**Characteristics of Somatic Mutations in Breast Cancer Patients with Germline Mutations.** (**A**) Three groups according to germline mutations: Germline-BRCA1/2, Germline-others (non-BRCA) and Others (non-carriers). (**B**) Somatic mutation positive detection rate among the three groups. (**C**) The difference of the mutation type distribution among the three groups. (**D**) The difference of the mutation genes among the three groups. \* P\<0.05. (**E**). PIK3CA mutation spectrum in the three groups.](aging-12-102783-g004){#f4}

DISCUSSION
==========

In this study, we performed an NGS-based comprehensive analysis of germline mutations in 62 cancer susceptibility genes of 524 unselected Chinese patients with various stages of breast cancer. The inclusion of unselected breast cancer patients with various stages provided a more representative germline mutation landscape among these patients. To our knowledge, by simultaneously interrogating 62 cancer susceptibility genes, our study is the first to elucidate a more comprehensive germline mutation profile of unselected breast cancer patients in the Southern Chinese population.

Our study demonstrated the detection of a total of 76 LP/P germline mutations in 15 genes from 58 patients, revealing an overall germline mutation rate of 11.1%. In contrast, another study of a large cohort of unselected breast cancer patients from North China has revealed an LP/P germline mutation rate of 9.2% (743/8085) \[[@r25]\]. By identifying the 15 genes potentially associated with increased genetic cancer susceptibility in our population, we could advocate for the inclusion of these 15 genes in the routine diagnostic workup for the assessment of genetic cancer predisposition instead of just testing for only *BRCA1/2* mutation status.

A number of studies have reported germline *BRCA1/2* mutation rate of approximately 5% in unselected breast cancer patients regardless of ethnicity \[[@r25]--[@r30]\]. Interestingly, we found that Chinese breast cancer patients have more frequent mutations in BRCA2 than in BRCA1 which differ from those in Western breast cancer patients \[[@r2]\]. Meanwhile, most of the BRCA2 mutation carriers (77.8%) in our cohort are HR+/HER2-. Therefore, we should not overlook the clinical value of germline mutation test in both TNBC and non-TNBC patients in China. Our analysis also revealed a mutation rate of 5.72% (30/524) in other cancer predisposition genes beyond *BRCA1/2*. Although the frequency of mutations in each gene is much lower than *BRCA1/2*, the collective mutation rate is more than the mutation rate of *BRCA1/2* in our cohort, providing important data for non-*BRCA1/2* mutations in breast cancer patients in Southern Chinese population. In contrast, the recent survey by Sun et al. revealed a mutation rate of 2.9% (237/8085) and 1% (83/8085) in beyond *BRCA1/2* genes and other cancer susceptibility genes, including mutations in *PALB2* (n=56), *TP53* (n=38), *ATM* (n=31), *RAD51D* (n=31), *RECQL* (n=30) and *CHEK2* (n=27) among the most frequent \[[@r25]\]. Interestingly, germline mutation rate of members of the Fanconi anaemia family of genes (including *BRCA2*, *PALB2*, *BRIP1*, *RAD51C*, *FANCA*, *FANCI* and *FANCL*) was 53.4% (31/58) among the patients with germline mutations in our cohort. These data strongly support the inclusion of not only *BRCA1/2*, but also the Fanconi anaemia genes for the assessment of germline mutations in breast cancer patients. In addition to *BRCA1/2*, growing evidences implicate germline mutations in genes involved in homologous recombination repair pathway such as *PALB2* in increased risk of breast and pancreatic cancer \[[@r6], [@r31]\] and improved sensitivity to therapeutic agents such as platinum-based chemotherapy and poly-ADP-ribose polymerase (PARP) inhibitors \[[@r32], [@r33]\]. A number of ongoing clinical trials are investigating the association of germline or somatic mutations in genes involved in homologous recombination repair including *PALB2* and response to different therapeutic agents including chemotherapy in the adjuvant or neoadjuvant setting, PARP inhibitors or checkpoint inhibitors \[[@r33]\].

Among the 62 genes interrogated for germline mutation profiling, no LP/P germline mutations were detected in 47 genes from our cohort, indicating that LP/P germline mutations in these genes are rare in our population. In addition, with the comprehensive germline mutational profiling using 62 cancer susceptibility genes, VUS were detected in more than 90% of the patients. With the increase in the use of NGS in clinical practice, a growing number of VUS are being reported \[[@r34]\]. Further studies are required to understand the function of these variants and their association with the development of disease, particularly in this population.

Furthermore, our study has identified distinct somatic mutations among the carriers of germline mutations and non-carriers. We found that mutation type distribution was different among patients carrying germline mutations in *BRCA1/2* than non-*BRCA1/2*. The mutation rates in *AKT1*, *CCND1*, *FGFR1*, and *PIK3CA* were different among the three groups. Interestingly, a patient with pathogenic germline *PALB2* mutation (p.Q921fs) also had somatic *PALB2* mutation (p.D525fs). The coexistence of LP/P germline and somatic mutations in this patient supports the "second-hit" hypothesis of breast cancer development \[[@r8]\].

There are two limitations in our study. First, all the 524 patients were from a single hospital with most of them from the Guangdong-Hong Kong-Macao Greater Bay Area. Second, no data for treatment responses and survival outcomes were available for analysis. Third, the sample size for certain molecular subtype was very limited. Larger nationwide multicenter studies should be conducted and long-term follow-up is needed to investigate the treatment and survival outcomes in germline mutation carriers.

CONCLUSIONS
===========

Our findings have potential clinical implications. Firstly, our study is the most comprehensive germline mutation study in unselected breast cancer patients in Southern China interrogating all breast or ovarian cancer-related genes listed in the US genetic guidelines. Secondly, our findings may be useful for selecting the subset of breast cancer patients to receive multigene panel testing. The inclusion of the 15 most common cancer susceptibility genes in cancer genetic predisposition screening is clinically relevant for the Chinese population. Thirdly, we explored the important difference of somatic mutation profiles among BRCA, non-BRCA germline mutations carriers and non-carriers. It provided a basis for better understanding of the tumor characteristics of patients with LP/P germline mutations.

MATERIALS AND METHODS
=====================

Patient selection
-----------------

This study was approved by the institutional review board of the Guangdong Provincial People\'s Hospital, and all participants provided written informed consent. From March 1, 2016 through December 31, 2018, a total of 524 breast cancer patients (AJCC stage Tis to IV) seen at the Department of Breast Cancer in Guangdong Provincial People\'s Hospital were offered germline sequencing. The disclosure of results was in accordance to an institutional protocol of matched tumor-germline DNA sequencing. Patients were unselected for age or personal and family history of cancers. Clinical and family history data were obtained from medical records. American Society of Clinical Oncology (ASCO) /College of American Pathologists (CAP) guidelines were used to define estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) positivity. All breast cancers samples were reviewed by breast pathologists. Genetic test results from this analysis were considered research and were not used for clinical decision making.

Preparation of plasma and tissue samples
----------------------------------------

Plasma was separated from blood samples collected in EDTA-treated tubes by centrifugation (1,500 x g, 4°C, 10 min). Plasma fractions were transferred into fresh tubes, centrifuged (16,000 x g, 4°C, 10 min) to remove cell debris, aliquoted into fresh tubes, and stored at -80°C until DNA extraction. Breast cancer tissue samples were obtained by biopsy and processed into FFPE cell blocks.

DNA extraction
--------------

Cell-free DNA (cfDNA) and genomic DNA were isolated from plasma and tissue samples using a QIAamp Circulating Nucleic Acid kit or QIAamp DNA FFPE tissue kit, respectively, according to the manufacturer's standard protocol (Qiagen, Hilden, Germany). Quantification of DNA obtained from plasma and tissue samples was performed using the Qubit dsDNA assay (Life Technologies, Carlsbad, CA, USA).

NGS library preparation, sequencing and data analysis
-----------------------------------------------------

DNA was subjected to end repair, phosphorylation and adaptor ligation. Fragments of size 200--400bp were selected by AMPure beads (Agencourt AMPure XP Kit), followed by hybridization with capture probe baits, hybrid selection with magnetic beads and PCR amplification. A bioanalyzer high-sensitivity DNA assay was subsequently performed to assess the quality and size of the fragments. Indexed paired samples were sequenced on Nextseq500 sequencer (Illumina, Inc., USA) with paired-end reads in a Clinical Laboratory Improvement Amendments (CLIA)/CAP-certified laboratory using a panel consisting of 520 cancer-related genes, spanning 1.64 megabases of the human genome (OncoScreen Plus panel, Burning Rock Biotech, Guangzhou, China) \[[@r35]\]. The panel was designed to capture whole exons of 312 genes and critical exons, introns and promoter regions of the remaining 208 genes. The panel also includes 62 cancer susceptibility genes for profiling the germline variants ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The 62 cancer susceptibility genes included in our study was based on the ACMG version 2.0 \[[@r36]\], National Comprehensive Cancer Network (NCCN) Guidelines Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 \[[@r37]\] and Genomics guidelines \[[@r38]--[@r40]\]. Sequencing data were analyzed using the Burrows-Wheeler Aligner followed by Genome Analysis Toolkit with an established somatic and germline variant calling pipeline.

Identification and classification of germline variants
------------------------------------------------------

The reported mutations were further confirmed with dbSNP and ClinVar databases. Additionally, other databases such as BRCA Exchange, and Breast Cancer Information Core \[[@r41]\] were searched along with publications archived in PubMed to confirm the assigned class of the mutation, the level of clinical and functional evidence of the mutation and identify novel mutations. Intervar \[[@r16]\], the computational tool for semi-automated variant interpretation, was used to aggregate the variant annotations from multiple databases, prediction tools and publications at a single site. In the absence of clinical data and *in vitro* functional assay, *in silico* predictions using algorithms that assess phylogenetic conservation and the likelihood of severe physiochemical alterations in the protein structure or function were utilized as prediction tools. All genetic annotations and nomenclature were based on GRCh37/hg19 build. The variants were classified according to the American Society of Medical Genetics and Genomics (ACMG) recommendations for standards of interpretation and reporting of sequence variations. The variants were organized into five classes as follows: pathogenic (Class 5), likely pathogenic (Class 4), variants of uncertain significance (Class 3,) likely benign (Class 2) and benign (Class 1) \[[@r36]\]. Without departing from the scope of this study, only pathogenic and likely pathogenic (LP/P) mutations were further analyzed.

Statistical methods
-------------------

Patient characteristics and sequencing results were summarized with descriptive statistics, including medians, means, and standard deviations for continuous data. Demographic, clinical, and pathologic characteristics were compared using the Chi-square test or Fisher's exact test (categorical variables), as applicable. P\<0.05 was considered statistically significant.

Ethics approval
---------------

Primary tumor biopsies were obtained using an Institutional Review Board approved protocol, and this study had been approved by the Ethics Committee of Guangdong Provincial People\'s Hospital. All patients provided written informed consent for translational research.

Supplementary Material
======================

**AUTHOR CONTRIBUTIONS:** NL, BC and GZ designed the study. BC, GZ, XL, GW, CR, KL, YW, HM, LW, MJ, CL, LG, JL, GW, YL, YZ participated in sample collection, sample processing, clinical information collection and data analysis. BC, XL, CR, JL and GZ analyzed and interpreted data. BC, NL and AL participated in manuscript writing. All authors read and approved the final manuscript.

**CONFLICTS OF INTEREST:** The authors declare that they have no conflicts of interests.

**FUNDING:** This work was supported by funds from Natural Science Foundation of Guangdong Province (2016A030313768, Ning Liao) and Research Funds from Guangzhou Municipal Science and Technology Project (201707010418, Ning Liao); High-level Hospital Construction Project (DFJH201921, Bo Chen); the National Natural Science Foundation of China (81902828, Bo Chen); the Fundamental Research Funds for the Central Universities (y2syD2192230, Bo Chen); and Medical Scientific Research Foundation of Guangdong Province (B2019039, Bo Chen). The funding body has no roles in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.

[^1]: Equal contribution
